AMPK: mediating the metabolic effects of salicylate-based drugs?

Gregory R. Steinberg; Madhumita Dandapani; D. Grahame Hardie

doi:10.1016/j.tem.2013.06.002

AMPK: mediating the metabolic effects of salicylate-based drugs?

Gregory R. Steinberg (Lead / Corresponding author), Madhumita Dandapani, D. Grahame Hardie (Lead / Corresponding author)

Research output: Contribution to journal › Review article › peer-review

69 Citations (Scopus)

Abstract

Salicylates are among the oldest medicinal compounds known to humans, and have been used to reduce fever, pain, and inflammation. The major oral salicylates are aspirin and salsalate, both of which are rapidly metabolized to salicylate in vivo. Owing to its acetyl group, aspirin irreversibly inhibits cyclo-oxygenases and thus blocks platelet aggregation, whereas salsalate has been used for treatment of inflammatory diseases such as rheumatoid arthritis. Recently, beneficial effects of salicylates in type 2 diabetes and cancer have been proposed. This has led to renewed interest in understanding how these simple molecules have such diverse and multifaceted effects. Here we discuss the idea that AMP-activated protein kinase (AMPK) might mediate some effects of salicylate-based drugs, particularly by modulating cellular metabolism.

Original language	English
Pages (from-to)	481-487
Number of pages	7
Journal	Trends in Endocrinology and Metabolism
Volume	24
Issue number	10
Early online date	19 Jul 2013
DOIs	https://doi.org/10.1016/j.tem.2013.06.002
Publication status	Published - Oct 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tem.2013.06.002

Rab Detection Initiative (Joint with Stanford School of Medicine, Max Plank Institute, Neuroscience Research Australia and Parkinsons Institute California)
Alessi, D. (Investigator) & Davies, P. (Investigator)
1/08/16 → 31/07/21
Project: Research
Non-canonical Pathways for Regulation of AMPK (Senior Investigator Award)
Hardie, G. (Investigator)
1/04/12 → 30/09/17
Project: Research

Cite this

@article{1dec08186a1a4755ac60e0e70a29db94,

title = "AMPK: mediating the metabolic effects of salicylate-based drugs?",

abstract = "Salicylates are among the oldest medicinal compounds known to humans, and have been used to reduce fever, pain, and inflammation. The major oral salicylates are aspirin and salsalate, both of which are rapidly metabolized to salicylate in vivo. Owing to its acetyl group, aspirin irreversibly inhibits cyclo-oxygenases and thus blocks platelet aggregation, whereas salsalate has been used for treatment of inflammatory diseases such as rheumatoid arthritis. Recently, beneficial effects of salicylates in type 2 diabetes and cancer have been proposed. This has led to renewed interest in understanding how these simple molecules have such diverse and multifaceted effects. Here we discuss the idea that AMP-activated protein kinase (AMPK) might mediate some effects of salicylate-based drugs, particularly by modulating cellular metabolism.",

author = "Steinberg, {Gregory R.} and Madhumita Dandapani and Hardie, {D. Grahame}",

note = "G.R.S. is supported by a Canada Research Chair in Metabolism and Obesity and grants from the Canadian Institutes of Health Research and the Canadian Diabetes Association. D.G.H. is supported by a Senior Investigator Award from the Wellcome Trust and a Programme Grant from Cancer Research UK, and by the pharmaceutical companies supporting the Division of Signal Transduction Therapy at Dundee (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck KgaA, Janssen Pharmaceutica, and Pfizer). M.D. was supported by a Clinical PhD studentship from the Wellcome Trust. Commissioned review article",

year = "2013",

month = oct,

doi = "10.1016/j.tem.2013.06.002",

language = "English",

volume = "24",

pages = "481--487",

journal = "Trends in Endocrinology and Metabolism",

issn = "1043-2760",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - AMPK

T2 - mediating the metabolic effects of salicylate-based drugs?

AU - Steinberg, Gregory R.

AU - Dandapani, Madhumita

AU - Hardie, D. Grahame

N1 - G.R.S. is supported by a Canada Research Chair in Metabolism and Obesity and grants from the Canadian Institutes of Health Research and the Canadian Diabetes Association. D.G.H. is supported by a Senior Investigator Award from the Wellcome Trust and a Programme Grant from Cancer Research UK, and by the pharmaceutical companies supporting the Division of Signal Transduction Therapy at Dundee (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck KgaA, Janssen Pharmaceutica, and Pfizer). M.D. was supported by a Clinical PhD studentship from the Wellcome Trust. Commissioned review article

PY - 2013/10

Y1 - 2013/10

N2 - Salicylates are among the oldest medicinal compounds known to humans, and have been used to reduce fever, pain, and inflammation. The major oral salicylates are aspirin and salsalate, both of which are rapidly metabolized to salicylate in vivo. Owing to its acetyl group, aspirin irreversibly inhibits cyclo-oxygenases and thus blocks platelet aggregation, whereas salsalate has been used for treatment of inflammatory diseases such as rheumatoid arthritis. Recently, beneficial effects of salicylates in type 2 diabetes and cancer have been proposed. This has led to renewed interest in understanding how these simple molecules have such diverse and multifaceted effects. Here we discuss the idea that AMP-activated protein kinase (AMPK) might mediate some effects of salicylate-based drugs, particularly by modulating cellular metabolism.

AB - Salicylates are among the oldest medicinal compounds known to humans, and have been used to reduce fever, pain, and inflammation. The major oral salicylates are aspirin and salsalate, both of which are rapidly metabolized to salicylate in vivo. Owing to its acetyl group, aspirin irreversibly inhibits cyclo-oxygenases and thus blocks platelet aggregation, whereas salsalate has been used for treatment of inflammatory diseases such as rheumatoid arthritis. Recently, beneficial effects of salicylates in type 2 diabetes and cancer have been proposed. This has led to renewed interest in understanding how these simple molecules have such diverse and multifaceted effects. Here we discuss the idea that AMP-activated protein kinase (AMPK) might mediate some effects of salicylate-based drugs, particularly by modulating cellular metabolism.

U2 - 10.1016/j.tem.2013.06.002

DO - 10.1016/j.tem.2013.06.002

M3 - Review article

C2 - 23871515

SN - 1043-2760

VL - 24

SP - 481

EP - 487

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

IS - 10

ER -

AMPK: mediating the metabolic effects of salicylate-based drugs?

Abstract

UN SDGs

Access to Document

Fingerprint

Projects

Rab Detection Initiative (Joint with Stanford School of Medicine, Max Plank Institute, Neuroscience Research Australia and Parkinsons Institute California)

Non-canonical Pathways for Regulation of AMPK (Senior Investigator Award)

Cite this